20May

[Comment] A new step towards targeting tau

Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkinsonian syndrome, early falls, supranuclear gaze palsy, and frontal cognitive impairment.1 In these patients, the response to levodopa is poor, and the disease rapidly leads to severe disability and death. Neuropathology shows aggregates of four microtubule-binding-domain-repeat (4R) tau in both neuronal and glial cells, and therefore immunotherapies targeting tau have been proposed as a potential treatment for the disease.

Ander nieuws

20May

[Review] CSF and blood biomarkers for Parkinson’s disease

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...

naar nieuwsitem

22Apr

Parkinson’s disease patient: ‘I can walk… it’s really helped me’

Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...

naar nieuwsitem

22Apr

Housebound Parkinson’s patients have movement restored

An electrical stimulus can help revive mobility for people with the disease, scientists have discove...

naar nieuwsitem